Professionals in drug discovery, drug development, and healthcare may not grasp the scale of the change that’s coming to their business thanks to generative AI models like GPT-4. They need to get up to speed fast if they want to stay competitive and incorporate generative AI into their work in a way that’s effective and safe. Fortunately there are plenty of people in the life sciences industry thinking about how to help with that. And one of them is Harry's guest this week, Lana Feng. She’s the CEO and co-founder of Huma.ai, and under her leadership the company has been working with OpenAI to find ways to adapt large language models for use inside biotech and pharmaceutical companies. GPT-4 and competing models are extremely powerful. But for a bunch of reasons that Lana explains in this episode, it wouldn’t be smart to apply them directly to the kinds of data gathering and data analysis that go on in the biopharma world. Huma.ai is working on that problem. They’re building on top of GPT-4 to make the model more private, more secure, more reliable, and more transparent, so that companies in drug development can really trust it with their data and not get tripped up by issues like the hallucination problem.